Latest Content


Shorts

Aaron Mantia
0:18
What Trend Are You Watching in 2027: CSafe's Aaron Mantia
7 hours ago
by
Aaron Mantia
Garrett Freeman
2:09
Onshoring Moves From Pledges to Steel in the Ground in 2027, Says Swisslog’s Garrett Freeman
7 hours ago
by
Garrett Freeman
Gregg Gorniak
0:53
Cencora’s Gregg Gorniak on AI After DSCSA Stabilization
a day ago
by
Gregg Gorniak
Vijay Paliwal
0:54
From Predicting Risk to Automating Intervention: The AI Shift to Watch in 2027
2 days ago
by
Vijay Paliwal
Mark Talens
0:38
PAXAFE’s Mark Talens on Why 2027 Is the Year Pharma Trusts AI in GxP Environments
5 days ago
by
Mark Talens
Nitin Jayakrishnan
0:59
Why the “People Supply Chain” Is a 2027 Risk for Pharma
6 days ago
by
Nitin Jayakrishnan
Matt Sample
1:09
Drug Price Cuts Are Challenging Supply Chain Economics Heading Into 2027
7 days ago
by
Matthew Sample
Henry Ames
0:57
Why Lane Risk Assessments Are Moving Beyond Historical Audits
8 days ago
by
Henry Ames
Danny Williams
0:47
Why Resilience Is the Throughline for 2027 Supply Chain Planning
12 days ago
by
Danny Williams
Kevin Cook
0:52
Kevin Cook: What to Watch In 2027
13 days ago
by
Kevin Cook

Supply Chain Signal: How Policy Pressures Are Converging on Pharma

Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.

Supply Chain Signal: How Policy Pressures Are Converging on Pharma

Why Temperature Control Is Now Pharma’s Make-or-Break Variable

Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes.

Why Temperature Control Is Now Pharma’s Make-or-Break Variable

EU Pharma Reform: Strategic Implications for US Drugmakers

The EU's pharma reform makes market protection more conditional. Here is how US drugmakers, especially startups, can adapt and use IP to complement it.

EU Pharma Reform: Strategic Implications for US Drugmakers

How the GLP-1 Boom Stress-Tests the Pharma Cold Chain

GLP-1 demand is straining pharma cold chain capacity, from tighter temperature thresholds and rising load rejections to fuel costs and trailer backlogs.

How the GLP-1 Boom Stress-Tests the Pharma Cold Chain

Podcasts


All News